NovaBridge Biosciences

https://www.novabridge.com

NovaBridge Biosciences is a global biotechnology platform company dedicated to accelerating access to innovative medicines. The company integrates deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Headquartered in Rockville, Maryland, NovaBridge Biosciences also maintains operations in Short Hills, New Jersey, and has a global presence with offices in Boston, Hong Kong, and Shanghai.

The company's core business focuses on developing therapies in immuno-oncology and ophthalmology. Its pipeline includes several clinical-stage programs such as Givastomig, a CLDN18.2 x 4-1BB bispecific antibody targeting gastric cancer; Ragistomig, a PD-L1 x 4-1BB bispecific antibody for solid tumors; and Uliledlimab, an anti-CD73 monoclonal antibody for non-small cell lung cancer (NSCLC). Through its subsidiary, Visara, Inc., NovaBridge Biosciences is also developing VIS-101, a VEGF-A/ANG2 bispecific antibody for retinal vascular diseases like wet age-related macular degeneration (AMD).

NovaBridge Biosciences underwent a significant corporate transformation in October 2025, changing its name from I-Mab and commencing trading on Nasdaq under the new ticker symbol NBP. This rebranding reflects its strategic shift to a global biotechnology platform utilizing a "hub-and-spoke" model to bring innovative medicines to worldwide markets. The leadership team includes Dr. Xi-Yong Fu as CEO, Wei Fu as Executive Chairman, and Mark Hagler, who was appointed President and Chief Commercial Officer in April 2026.

Latest updates

NovaBridge Taps Pharma Veteran Hagler to Drive Commercialization

Event summary

  • NovaBridge Biosciences appointed Mark Hagler as President and Chief Commercial Officer, effective immediately.
  • Hagler previously served as Chief Commercial Officer for Sun Pharmaceuticals, overseeing a $1B+ portfolio.
  • Hagler’s experience includes commercial strategy for Abraxane and global launch of Afinitor indications.
  • The appointment aims to accelerate development of givastomig (gastric cancer) and VIS-101 (wet AMD).

The big picture

NovaBridge’s move to bring in a seasoned commercial executive like Hagler signals a shift towards prioritizing commercial readiness as it advances its pipeline. With a combined market potential exceeding billions of dollars, the success of givastomig and VIS-101 is crucial for NovaBridge’s long-term viability. Hagler's experience in oncology and ophthalmology, two highly competitive and regulated markets, will be essential for navigating the challenges ahead.

What we're watching

Execution Risk
Hagler’s success will hinge on his ability to rapidly integrate and align NovaBridge’s internal teams around a unified commercial strategy, particularly given the complexity of the pipeline.
Clinical Milestones
The timing and results of pivotal studies for givastomig and VIS-101 will be critical in validating Hagler’s strategy and driving shareholder value.
Partner Dynamics
The ongoing collaboration with ABL Bio for ragistomig and Visara for VIS-101 will require careful management to ensure alignment and avoid potential conflicts.

NovaBridge Advances Pipeline, Burns Cash as Global Biotech Platform Takes Shape

Event summary

  • NovaBridge reported $210.8 million in cash as of December 31, 2025, expected to fund operations through 2028.
  • Givastomig, a gastric cancer treatment, showed a 75% objective response rate in Phase 1b trials and is eligible for FDA’s Accelerated Approval Pathway.
  • VIS-101, targeting wet AMD, demonstrated rapid and durable responses in Phase 2a trials and is poised to begin Phase 2b studies in H2 2026.
  • The company expanded its Board of Directors and Executive Team, including appointments like Emmett T. Cunningham, Jr. and Kyler Lei.

The big picture

NovaBridge's transformation into a global biotech platform, while promising, is predicated on the success of its two lead programs and the efficient management of its expanding cost base. The company's strategy of acquiring and accelerating assets, coupled with a complex organizational structure involving Visara, introduces operational and financial risks that investors should carefully consider. The company's current valuation reflects significant potential, but also carries the risk of substantial losses if clinical or commercial milestones are not achieved.

What we're watching

Regulatory Risk
The FDA’s Accelerated Approval Pathway for givastomig hinges on continued positive data and a favorable assessment of the benefit-risk profile, which could be subject to change.
Cash Burn
While the company projects runway through 2028, the significant increase in R&D expenses, driven by acquisitions and clinical trials, warrants close monitoring of cash burn rates and potential future financing needs.
Commercial Execution
Success of VIS-101 will depend on its ability to demonstrate a clear advantage over existing therapies in wet AMD and secure favorable reimbursement, given the competitive landscape.

NovaBridge Secures FDA Alignment on Accelerated Approval Pathway for Givastomig

Event summary

  • NovaBridge received written minutes confirming FDA alignment on an accelerated approval pathway for givastomig in 1L Her2-, CLDN 18.2+, PD-L1+ GEC patients.
  • The company plans to initiate a registrational Phase 3 combination trial in Q4 2026, using objective response rate (ORR) as the primary endpoint.
  • Phase 1b data showed a 75% ORR with givastomig in combination with immunochemotherapy, alongside a median progression-free survival (mPFS) of 16.9 months.
  • Givastomig is jointly developed with ABL Bio, with NovaBridge holding worldwide rights excluding Greater China and South Korea.

The big picture

NovaBridge's progress with givastomig underscores the increasing focus on targeted therapies for gastroesophageal cancer, a market with significant unmet need. The accelerated approval pathway, if realized, would significantly shorten the time to market and provide a competitive advantage, but also carries the risk of post-approval scrutiny if confirmatory trials fail to validate initial findings. The partnership with ABL Bio, while beneficial for resource sharing, introduces a layer of complexity in decision-making and potential conflict.

What we're watching

Regulatory Risk
While the Type B meeting was positive, final approval hinges on Phase 3 trial success and FDA acceptance of ORR as a primary endpoint, introducing potential regulatory hurdles.
Clinical Execution
The rapid timeline for Phase 3 initiation (Q4 2026) suggests aggressive execution; delays in patient enrollment or trial design could impact the accelerated approval pathway.
Partner Dynamics
The shared rights structure with ABL Bio introduces potential for disagreements regarding development strategy or commercialization, which could impact givastomig’s progress.

NovaBridge VIS-101 Data Bolsters Dual VEGF/ANG-2 Approach in Wet AMD

Event summary

  • NovaBridge and Visara announced positive topline Phase 2a data for VIS-101, a tetravalent, dual VEGF-A/ANG-2 inhibitor, in wet AMD.
  • VIS-101 demonstrated mean BCVA improvements of >10 ETDRS letters and median CST reductions of 100-150 mm.
  • Approximately half of treatment-naïve patients remained retreatment-free at 6 months following three loading doses.
  • A Phase 2b dose-determining study is planned for H2 2026, with a global Phase 3 program anticipated in 2027.
  • The study enrolled 38 patients in China, randomized 2:1 between 6mg and 3mg dose cohorts.

The big picture

The positive VIS-101 data validates the dual VEGF-A/ANG-2 inhibition approach, which is gaining traction in wet AMD treatment following the introduction of Faricimab. NovaBridge’s strategy of acquiring and accelerating development of differentiated assets, combined with a ‘hub-and-spoke’ business model, positions them to capitalize on unmet needs in retinal vascular diseases, but execution risk remains high given the competitive landscape and lengthy clinical development timelines.

What we're watching

Clinical Execution
The success of VIS-101 hinges on the Phase 2b dose-determining study; failure to identify an optimal dose could delay or derail the program.
Competitive Landscape
Given the established market presence of competitors like Faricimab, VIS-101 will need to demonstrate a clear and sustained advantage in durability and efficacy to achieve significant market share.
Regulatory Pathway
The Chinese regulatory environment will be critical for early commercialization, and the speed of approval could influence NovaBridge's broader global strategy.

NovaBridge to Detail VIS-101 Phase 2a Data Next Week

Event summary

  • NovaBridge Biosciences will host a business update call on March 9, 2026, at 9:00 AM ET to review Phase 2a clinical data for VIS-101.
  • VIS-101 is a bispecific, tetravalent dual VEGF-A/ANG-2 inhibitor targeting wet AMD, DME, and RVO.
  • Visara, a majority-owned subsidiary of NovaBridge, holds global rights to VIS-101 outside of Greater China and certain Asian territories, licensed to Everest Medicines.
  • The call will feature executives from NovaBridge, Visara, and external advisors, including Dr. Emmett Cunningham and Dr. Carlos Quezada-Ruiz.

The big picture

NovaBridge’s strategy of acquiring and accelerating clinical assets, particularly through its Visara subsidiary, represents a bet on a platform model within the highly competitive ophthalmology market. VIS-101’s success is crucial for validating this approach and attracting further investment, especially given the crowded landscape of AMD treatments. The licensing arrangement with Everest Medicines introduces a layer of complexity, as their performance will directly impact NovaBridge’s potential returns.

What we're watching

Clinical Efficacy
The Phase 2a data will be critical in assessing VIS-101's efficacy compared to existing VEGF inhibitors, particularly given its dual-targeting mechanism; a lack of compelling differentiation could significantly impact its commercial prospects.
Commercialization
The ongoing partnership with Everest Medicines for territories outside of China will be under scrutiny, as the success of VIS-101 hinges on their ability to effectively navigate those markets and secure reimbursement.
Governance
The significant involvement of Emmett Cunningham, both at Visara and on NovaBridge’s board, raises questions about potential conflicts of interest and the long-term strategic alignment between the two companies.

NovaBridge to Detail Pipeline Progress at Leerink Conference

Event summary

  • NovaBridge Biosciences’ management will present at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026.
  • The presentation will be a fireside chat accessible via webcast starting at 8:00 AM ET.
  • NovaBridge’s pipeline is led by givastomig (Claudin 18.2 x 4-1BB bispecific antibody) and VIS-101 (VEGF-A and ANG-2 targeting biologic).
  • Givastomig recently announced positive topline results from a Phase 1b study for gastric cancer.

The big picture

NovaBridge’s participation in the Leerink conference signals an effort to maintain investor visibility and highlight progress in its pipeline. The company’s strategy of acquiring and accelerating assets, combined with its focus on bispecific antibodies, reflects a broader trend in the biotech sector towards more targeted and potentially more effective therapies. The success of givastomig, in particular, will be a key determinant of NovaBridge’s valuation and future growth prospects.

What we're watching

Clinical Data
The conference presentation will likely focus on the Phase 2 data for givastomig; investors should assess the clarity and robustness of these findings and their implications for potential regulatory pathways.
Partner Dynamics
The ongoing collaboration with ABL Bio on ragistomig warrants scrutiny; any shifts in the partnership structure or development timelines could impact NovaBridge’s overall pipeline strategy.
Market Positioning
Given the competitive landscape for VEGF-A/ANG-2 inhibitors, the presentation should clarify how VIS-101’s profile differentiates it and whether Visara’s commercialization strategy can secure market share.

NovaBridge Adds Biotech Veteran Cunningham as Vice Chairman

Event summary

  • NovaBridge Biosciences appointed Emmett T. Cunningham, Jr., MD, PhD, MPH, as Vice Chairman of the Board, effective February 19, 2026.
  • Dr. Cunningham is also Co-Founder and Executive Chairman of NovaBridge subsidiary, Visara, Inc., and will join the Board’s Research and Development Committee.
  • Dr. Cunningham previously held senior roles at Blackstone Group L.P., Clarus Ventures, LLC, Eyetech, Inc., and Pfizer.
  • He brings over 25 years of experience in venture capital, biopharma leadership, and directorship.

The big picture

NovaBridge’s appointment of Emmett Cunningham signals a deliberate effort to bolster its platform model with deep industry expertise and a focus on accelerating drug development. Cunningham’s extensive venture capital background suggests a heightened emphasis on shareholder value and a potential shift towards more disciplined capital allocation. This move comes as NovaBridge seeks to advance its pipeline, including givastomig and VIS-101, and compete in a crowded biotech landscape.

What we're watching

R&D Focus
Dr. Cunningham’s involvement in the R&D Committee suggests a potential shift towards accelerated drug development timelines and a more aggressive innovation strategy, which could impact burn rates and pipeline progression.
Visara Synergy
The dual role at Visara and NovaBridge raises questions about potential resource allocation and strategic alignment between the two entities, and whether Visara’s assets will be prioritized.
Governance Dynamics
With a seasoned investor and former executive joining the board, NovaBridge’s governance structure may become more financially oriented, potentially influencing long-term strategic decisions and shareholder returns.

NovaBridge Advances Gastric Cancer Candidate into Phase 2 Trial

Event summary

  • NovaBridge initiated a global, randomized Phase 2 study of givastomig, a CLDN18.2 x 4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX6 for 1L metastatic gastric cancer.
  • Phase 1b data showed a 75% objective response rate (ORR), a median progression-free survival (mPFS) of 16.9 months, and an 82% 6-month landmark PFS.
  • The Phase 2 study aims to enroll approximately 180 patients and expects top-line results in 2027.
  • Givastomig is being jointly developed with ABL Bio, with NovaBridge holding worldwide rights excluding Greater China and South Korea.

The big picture

The gastric cancer market represents a significant unmet need and a $12 billion opportunity by 2030, driving intense competition for effective therapies. NovaBridge’s givastomig, with its bispecific antibody design targeting CLDN18.2 and activating T cells, aims to address this need, but faces challenges in demonstrating superior efficacy and safety compared to existing immunotherapies and chemotherapy regimens. The Phase 2 trial results will be a crucial inflection point for the company’s valuation and future prospects.

What we're watching

Clinical Efficacy
The Phase 2 trial’s results will be critical in validating the Phase 1b data and determining if givastomig can meaningfully improve patient outcomes compared to standard of care, particularly given the competitive landscape in gastric cancer treatment.
Regulatory Pathway
The success of the Phase 2 trial will heavily influence NovaBridge’s ability to secure regulatory approval, and the FDA’s assessment of the combination therapy’s safety profile will be a key factor in its potential market adoption.
Partner Dynamics
The ongoing collaboration with ABL Bio will be important to monitor, as shared development costs and rights could impact NovaBridge’s profitability and future strategic options.

NovaBridge Executive Chairman Invests $5 Million in Open Market Purchases

Event summary

  • Fu Wei, Executive Chairman of NovaBridge Biosciences, intends to purchase up to $5 million of the company’s American Depositary Shares (ADS) in open market transactions.
  • The purchases began on January 15, 2026, and are ongoing.
  • The investment follows the release of positive Phase 1b dose expansion data for givastomig in gastric cancer patients.
  • NovaBridge is a global biotechnology platform company focused on accelerating access to innovative medicines.

The big picture

The open market purchase by the Executive Chairman signals a vote of confidence in NovaBridge’s strategy and pipeline, particularly following the positive Phase 1b data for givastomig. This move could be intended to stabilize the stock price or attract other investors, but the lack of a guaranteed purchase amount introduces uncertainty. The investment underscores the ongoing trend of executive leadership taking a more active role in demonstrating commitment to their companies, especially in the volatile biotechnology sector.

What we're watching

Governance Dynamics
The size of Fu Wei’s investment, while substantial, is not a guarantee of future capital deployment, and the lack of a fixed purchase timeline suggests a degree of flexibility in his strategy.
Clinical Execution
How the company manages the expectations set by the Phase 1b data for givastomig will be critical; premature hype could lead to investor disappointment if subsequent trials fail to deliver.
Market Sentiment
Whether the open market purchase can sustainably bolster investor confidence in NovaBridge will depend on broader market conditions and the company’s ability to consistently demonstrate progress.

NovaBridge Rings Nasdaq Bell, Joins Biotech Index Amid Pipeline Progression

Event summary

  • NovaBridge Executive Chairman Fu Wei and CEO Sean Fu will ring the Nasdaq Opening Bell on January 2, 2026, at 9:15 AM ET.
  • The company has been added to the Nasdaq Biotech Index (NBI), effective December 19, 2025.
  • NovaBridge’s pipeline is led by givastomig (Claudin 18.2 x 4-1BB bispecific antibody) and VIS-101 (VEGF-A/ANG-2 bifunctional biologic).
  • NovaBridge is collaborating with ABL Bio for the development of ragistomig (PD-L1/4-1BB bispecific antibody).

The big picture

NovaBridge’s inclusion in the Nasdaq Biotech Index and the planned bell-ringing ceremony signal a desire to elevate the company’s profile and attract investment. The company’s strategy of acquiring and accelerating assets through a ‘hub-and-spoke’ model is increasingly common in biotech, but its success hinges on efficient execution and clinical trial outcomes. The company's reliance on partnerships, like that with ABL Bio, introduces additional layers of risk.

What we're watching

Pipeline Risk
The success of givastomig and VIS-101, particularly VIS-101’s Phase 2 trial, will be critical to justifying the index inclusion and maintaining investor confidence, given the inherent risks associated with clinical development.
Partner Dynamics
The ongoing collaboration with ABL Bio for ragistomig’s development will need to remain productive, as any disruption could impact NovaBridge’s broader oncology pipeline.
Market Positioning
How NovaBridge leverages its ‘hub-and-spoke’ business model to accelerate drug development will determine if the company can truly establish itself as an industry leader and deliver on its shareholder value promises.
CID: 525